SlideShare a Scribd company logo
Liraglutide - Comprehensive patent search
Report Details:
Published:November 2012
No. of Pages:
Price: Single User License – US$7200




Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and
without the wait.
Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline
Developer minimises the risk of wasted developments or legal action, by providing you with
nothing less than the very best in comprehensive patent information. Searched and analysed by
highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer
delivers results you can rely on. And that means your staff can concentrate on how the patent
landscape affects your business, rather than trying to source reliable patent information.
Pipeline Developer features:
•Comprehensive patent searching, covering the world's key territories (see 'search coverage'
 below)
•Identifies patents covering molecule, formulation, process, use, combination and assay
 techniques (see 'Patent Categories Identified'below)
•Patent identification, categorisation and interpretation
•Grouped by patent family and assigned to development categories based on Interpretation of key
 aspects of the patent claims
•Manual filtration of patents not relevant to generic development
•Updated on a monthly basis, including changes to patent families, statuses, and litigation
•Enables fast analysis and verification by hyper-linking to crucial patent documents and national
 registers
Patent Categories Identified:
1. Molecular Form
 a) Molecule Patents
 b) Salts, Hydrates & Solvates
 c) Polymorphic Forms
 d) Other Molecular Forms
2. Active Ingredient Preparation
 a) Intermediates & Preparation Thereof
 b) Final Synthetic Stages
 c) Complete Synthesis
 d) Purification Methods
e) Fermentation Methods
 f) Biotechnology
3. Formulations & Methods Thereof
 a) General Formulations & Methods
 b) Injectable Formulations
 c) Oral Formulations
 d) Other Administration-Specific Formulations
 e) Excipients, Kits & Packaging
4. Related Medical Use & Administration
 a) New Use Related to Main Indication
 b) Dosing Regimen/Administration Conditions
5. Active Ingredient Combinations
 a) Novel Combinations
 b) Use of Combinations
 c) Dosing Regimen & Administration Conditions for Combinations
6. Analytical Methods
 a) Assaying Methods
 b) Methods of Determining Patient Suitability
Search coverage:
Clicking on a patent family displays detailed information on the 'Core' and 'Non-Core' 'Patent
Family Equivalents'. 'Core Patent Family Equivalents' are equivalent patents from territories that
are individually verified and monitored for changes, including British, German, Spanish, French,
US, Canadian, Australian, European, and PCT patents. Statuses are also monitored and updated.
'Extended Patent Family Equivalents' are equivalent patents found through the INPADOC
database, increasing the search coverage to 70 countries.
Patent and national register access:
Clicking on a listed patent/application number or text or image link will launch a pop-up window
containing an image of the patent, enabling easy analysis of the patent documents. Clicking on a
register link launches a pop-up window with the patent office register extract for that patent. This
allows investigation into the examination status of a pending patent, opposition of a granted patent
and/or payment of maintenance fees. Please note that no extra charges apply to accessing or
downloading documents of any kind.
Litigation alerts:
Informing you of developments in court, litigation alerts can also be accessed by clicking on the
litigation symbol next to the status, with links to judgements where available.
Updating:
To take the time and hassle out of monitoring and updating a large number of patents, all Pipeline
Developer reporting is updated on a monthly basis. Convenient change flags identify new patent
families, new patent family members, changes in statuses and litigation alerts.
Legal status and transaction history:
You can also find legal status and transaction history for 'Extended Patent Family Equivalents' by
clicking on the INPADOC Family/Legal Status button for 65 additional territories.
Reporting and access:
All data can be exported into Microsoft Excel and print friendly versions for ease of data
manipulation and reporting. Company details are confidential and all data is SSL secure. Five
users per company are permitted and access levels are controlled by a nominated 'company
administrator'.
Pipeline Developer is just one of the benchmark products from GenericsWeb's Pipeline Patent
Intelligence product suite.


Get your copy of this report @
http://www.reportsnreports.com/reports/206873-liraglutide-comprehensive-patent-search.html

Major points covered in Table of Contents of this report include
N/A


Contact: sales@reportsandreports.com for more information.

More Related Content

What's hot

FDA MAUDE DB Text Search Insights
FDA MAUDE DB Text Search InsightsFDA MAUDE DB Text Search Insights
FDA MAUDE DB Text Search Insights
TrevorSchmaeling
 
Cytokinetics, incorporated – product pipeline review – 2012
Cytokinetics, incorporated – product pipeline review – 2012Cytokinetics, incorporated – product pipeline review – 2012
Cytokinetics, incorporated – product pipeline review – 2012
Rose088
 
Practical XEVMPD experience; once upon a time there was a perfectly clean dat...
Practical XEVMPD experience; once upon a time there was a perfectly clean dat...Practical XEVMPD experience; once upon a time there was a perfectly clean dat...
Practical XEVMPD experience; once upon a time there was a perfectly clean dat...
Qdossier B.V.
 
Clinical sas course syllabus
Clinical sas course syllabusClinical sas course syllabus
Clinical sas course syllabus
Softlogic Systems
 
Incorporating Commercial and Private Data into an Open Linked Data Platform f...
Incorporating Commercial and Private Data into an Open Linked Data Platform f...Incorporating Commercial and Private Data into an Open Linked Data Platform f...
Incorporating Commercial and Private Data into an Open Linked Data Platform f...
Alasdair Gray
 
American CryoStem 2016 Year End Update
American CryoStem 2016 Year End UpdateAmerican CryoStem 2016 Year End Update
American CryoStem 2016 Year End Update
AmericanCryoStem
 
Lab data integrity
Lab data integrity Lab data integrity
Lab data integrity
Rajesh Kapoor
 
Planning for the New Individual Case Safety Report (ICSR) International Stand...
Planning for the New Individual Case Safety Report (ICSR) International Stand...Planning for the New Individual Case Safety Report (ICSR) International Stand...
Planning for the New Individual Case Safety Report (ICSR) International Stand...Perficient
 
FDA's top data integrity issues during the inspections
FDA's top data integrity issues during the inspectionsFDA's top data integrity issues during the inspections
FDA's top data integrity issues during the inspections
Kiran Kota
 
Investigating future prospects of electronic medical device labeling
Investigating future prospects of electronic medical device labelingInvestigating future prospects of electronic medical device labeling
Investigating future prospects of electronic medical device labeling
Myron Finseth, MSc
 
Data integrity
Data integrityData integrity
Data integrity
Dr. Nandan Dhir Ph.D.
 
Vaxon biotech – product pipeline review – 2012
Vaxon biotech – product pipeline review – 2012Vaxon biotech – product pipeline review – 2012
Vaxon biotech – product pipeline review – 2012
Rose088
 
FDA Data Integrity: Misconceptions of 21 CFR Part 11
FDA Data Integrity: Misconceptions of 21 CFR Part 11 FDA Data Integrity: Misconceptions of 21 CFR Part 11
FDA Data Integrity: Misconceptions of 21 CFR Part 11
EduQuest, Inc.
 
BIA 10-2474 in GtoPdb
BIA 10-2474 in GtoPdbBIA 10-2474 in GtoPdb
BIA 10-2474 in GtoPdb
Chris Southan
 
Seeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA OptionSeeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA Option
QPS Holdings, LLC
 
Data integrity nishodh 01092016
Data integrity nishodh 01092016Data integrity nishodh 01092016
Data integrity nishodh 01092016
Nishodh Saxena Ph. D.
 
Data integrity - Regulatory Perspective and Challenges:
Data integrity - Regulatory Perspective and Challenges: Data integrity - Regulatory Perspective and Challenges:
Data integrity - Regulatory Perspective and Challenges:
santoshnarla
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
Piyush Tripathi
 
New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...
New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...
New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...
NAMSA
 

What's hot (20)

FDA MAUDE DB Text Search Insights
FDA MAUDE DB Text Search InsightsFDA MAUDE DB Text Search Insights
FDA MAUDE DB Text Search Insights
 
Cytokinetics, incorporated – product pipeline review – 2012
Cytokinetics, incorporated – product pipeline review – 2012Cytokinetics, incorporated – product pipeline review – 2012
Cytokinetics, incorporated – product pipeline review – 2012
 
Practical XEVMPD experience; once upon a time there was a perfectly clean dat...
Practical XEVMPD experience; once upon a time there was a perfectly clean dat...Practical XEVMPD experience; once upon a time there was a perfectly clean dat...
Practical XEVMPD experience; once upon a time there was a perfectly clean dat...
 
Clinical sas course syllabus
Clinical sas course syllabusClinical sas course syllabus
Clinical sas course syllabus
 
Incorporating Commercial and Private Data into an Open Linked Data Platform f...
Incorporating Commercial and Private Data into an Open Linked Data Platform f...Incorporating Commercial and Private Data into an Open Linked Data Platform f...
Incorporating Commercial and Private Data into an Open Linked Data Platform f...
 
American CryoStem 2016 Year End Update
American CryoStem 2016 Year End UpdateAmerican CryoStem 2016 Year End Update
American CryoStem 2016 Year End Update
 
Lab data integrity
Lab data integrity Lab data integrity
Lab data integrity
 
Planning for the New Individual Case Safety Report (ICSR) International Stand...
Planning for the New Individual Case Safety Report (ICSR) International Stand...Planning for the New Individual Case Safety Report (ICSR) International Stand...
Planning for the New Individual Case Safety Report (ICSR) International Stand...
 
FDA's top data integrity issues during the inspections
FDA's top data integrity issues during the inspectionsFDA's top data integrity issues during the inspections
FDA's top data integrity issues during the inspections
 
Investigating future prospects of electronic medical device labeling
Investigating future prospects of electronic medical device labelingInvestigating future prospects of electronic medical device labeling
Investigating future prospects of electronic medical device labeling
 
Data integrity
Data integrityData integrity
Data integrity
 
Vaxon biotech – product pipeline review – 2012
Vaxon biotech – product pipeline review – 2012Vaxon biotech – product pipeline review – 2012
Vaxon biotech – product pipeline review – 2012
 
FDA Data Integrity: Misconceptions of 21 CFR Part 11
FDA Data Integrity: Misconceptions of 21 CFR Part 11 FDA Data Integrity: Misconceptions of 21 CFR Part 11
FDA Data Integrity: Misconceptions of 21 CFR Part 11
 
BIA 10-2474 in GtoPdb
BIA 10-2474 in GtoPdbBIA 10-2474 in GtoPdb
BIA 10-2474 in GtoPdb
 
Seeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA OptionSeeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA Option
 
Delta GMP Data Integrity Sept2016
Delta GMP Data Integrity Sept2016Delta GMP Data Integrity Sept2016
Delta GMP Data Integrity Sept2016
 
Data integrity nishodh 01092016
Data integrity nishodh 01092016Data integrity nishodh 01092016
Data integrity nishodh 01092016
 
Data integrity - Regulatory Perspective and Challenges:
Data integrity - Regulatory Perspective and Challenges: Data integrity - Regulatory Perspective and Challenges:
Data integrity - Regulatory Perspective and Challenges:
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
 
New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...
New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...
New FDA Refuse to Accept Policy for 510(k)s and Acceptance Review Process for...
 

Viewers also liked

Velocity Berlin 2011 - Keynote Systems
Velocity Berlin 2011 - Keynote SystemsVelocity Berlin 2011 - Keynote Systems
Velocity Berlin 2011 - Keynote SystemsKeynote Mobile Testing
 
Natural, Organic, and Eco-Friendly Pet Products in the U.S., 4th Edition
Natural, Organic, and Eco-Friendly Pet Products in the U.S., 4th EditionNatural, Organic, and Eco-Friendly Pet Products in the U.S., 4th Edition
Natural, Organic, and Eco-Friendly Pet Products in the U.S., 4th EditionReportsnReports
 
Customer Experience Suite Townsville
Customer Experience Suite   TownsvilleCustomer Experience Suite   Townsville
Customer Experience Suite TownsvilleMike Handes
 
Hidrósfera 2
Hidrósfera 2 Hidrósfera 2
Hidrósfera 2
Quezada G
 
Puppet - Module entwickeln - Von der Planung bis zur Umsetzung
Puppet - Module entwickeln - Von der Planung bis zur UmsetzungPuppet - Module entwickeln - Von der Planung bis zur Umsetzung
Puppet - Module entwickeln - Von der Planung bis zur Umsetzunginovex GmbH
 
Código de ética do contabilista cepc
Código de ética do contabilista cepcCódigo de ética do contabilista cepc
Código de ética do contabilista cepcrazonetecontabil
 
National Brands: Prioritizing Efforts for Scale
National Brands: Prioritizing Efforts for Scale National Brands: Prioritizing Efforts for Scale
National Brands: Prioritizing Efforts for Scale
Expion
 
Non-Life Insurance in Japan, Key Trends and Opportunities to 2016
Non-Life Insurance in Japan, Key Trends and Opportunities to 2016Non-Life Insurance in Japan, Key Trends and Opportunities to 2016
Non-Life Insurance in Japan, Key Trends and Opportunities to 2016ReportsnReports
 
Non-Life Insurance in Canada, Key Trends and Opportunities to 2016
Non-Life Insurance in Canada, Key Trends and Opportunities to 2016Non-Life Insurance in Canada, Key Trends and Opportunities to 2016
Non-Life Insurance in Canada, Key Trends and Opportunities to 2016ReportsnReports
 
Strategic Alliances in the Machine-to-Machine (M2M) Ecosystem
Strategic Alliances in the Machine-to-Machine (M2M) EcosystemStrategic Alliances in the Machine-to-Machine (M2M) Ecosystem
Strategic Alliances in the Machine-to-Machine (M2M) EcosystemReportsnReports
 
Chon font chu cho thuong hieu truong cao dang quoc te Kent
Chon font chu cho thuong hieu truong cao dang quoc te KentChon font chu cho thuong hieu truong cao dang quoc te Kent
Chon font chu cho thuong hieu truong cao dang quoc te Kent
Kent College
 
Nedim sabic Million SEO Campixx2014
Nedim sabic Million SEO Campixx2014Nedim sabic Million SEO Campixx2014
Nedim sabic Million SEO Campixx2014
Spirofrog & Cleantech Europe - Jobs & Career
 
US Coagulation Testing Market: Innovative Technologies and Emerging Business ...
US Coagulation Testing Market: Innovative Technologies and Emerging Business ...US Coagulation Testing Market: Innovative Technologies and Emerging Business ...
US Coagulation Testing Market: Innovative Technologies and Emerging Business ...ReportsnReports
 
Kayadari haji
Kayadari hajiKayadari haji
Kayadari haji
nufir2203
 

Viewers also liked (17)

Velocity Berlin 2011 - Keynote Systems
Velocity Berlin 2011 - Keynote SystemsVelocity Berlin 2011 - Keynote Systems
Velocity Berlin 2011 - Keynote Systems
 
мз
мзмз
мз
 
Natural, Organic, and Eco-Friendly Pet Products in the U.S., 4th Edition
Natural, Organic, and Eco-Friendly Pet Products in the U.S., 4th EditionNatural, Organic, and Eco-Friendly Pet Products in the U.S., 4th Edition
Natural, Organic, and Eco-Friendly Pet Products in the U.S., 4th Edition
 
Customer Experience Suite Townsville
Customer Experience Suite   TownsvilleCustomer Experience Suite   Townsville
Customer Experience Suite Townsville
 
Hidrósfera 2
Hidrósfera 2 Hidrósfera 2
Hidrósfera 2
 
Puppet - Module entwickeln - Von der Planung bis zur Umsetzung
Puppet - Module entwickeln - Von der Planung bis zur UmsetzungPuppet - Module entwickeln - Von der Planung bis zur Umsetzung
Puppet - Module entwickeln - Von der Planung bis zur Umsetzung
 
Código de ética do contabilista cepc
Código de ética do contabilista cepcCódigo de ética do contabilista cepc
Código de ética do contabilista cepc
 
National Brands: Prioritizing Efforts for Scale
National Brands: Prioritizing Efforts for Scale National Brands: Prioritizing Efforts for Scale
National Brands: Prioritizing Efforts for Scale
 
Non-Life Insurance in Japan, Key Trends and Opportunities to 2016
Non-Life Insurance in Japan, Key Trends and Opportunities to 2016Non-Life Insurance in Japan, Key Trends and Opportunities to 2016
Non-Life Insurance in Japan, Key Trends and Opportunities to 2016
 
Non-Life Insurance in Canada, Key Trends and Opportunities to 2016
Non-Life Insurance in Canada, Key Trends and Opportunities to 2016Non-Life Insurance in Canada, Key Trends and Opportunities to 2016
Non-Life Insurance in Canada, Key Trends and Opportunities to 2016
 
Caeza
CaezaCaeza
Caeza
 
Strategic Alliances in the Machine-to-Machine (M2M) Ecosystem
Strategic Alliances in the Machine-to-Machine (M2M) EcosystemStrategic Alliances in the Machine-to-Machine (M2M) Ecosystem
Strategic Alliances in the Machine-to-Machine (M2M) Ecosystem
 
Chon font chu cho thuong hieu truong cao dang quoc te Kent
Chon font chu cho thuong hieu truong cao dang quoc te KentChon font chu cho thuong hieu truong cao dang quoc te Kent
Chon font chu cho thuong hieu truong cao dang quoc te Kent
 
Nedim sabic Million SEO Campixx2014
Nedim sabic Million SEO Campixx2014Nedim sabic Million SEO Campixx2014
Nedim sabic Million SEO Campixx2014
 
US Coagulation Testing Market: Innovative Technologies and Emerging Business ...
US Coagulation Testing Market: Innovative Technologies and Emerging Business ...US Coagulation Testing Market: Innovative Technologies and Emerging Business ...
US Coagulation Testing Market: Innovative Technologies and Emerging Business ...
 
Kayadari haji
Kayadari hajiKayadari haji
Kayadari haji
 
Refractories to 2016
Refractories to 2016Refractories to 2016
Refractories to 2016
 

Similar to Liraglutide - Comprehensive patent search

US FDA Quality Metrics Technical Conformance Guide
US FDA  Quality Metrics Technical  Conformance GuideUS FDA  Quality Metrics Technical  Conformance Guide
US FDA Quality Metrics Technical Conformance Guide
GMP EDUCATION : Not for Profit Organization
 
Implementing Agile in an FDA Regulated Environment
Implementing Agile in an FDA Regulated EnvironmentImplementing Agile in an FDA Regulated Environment
Implementing Agile in an FDA Regulated Environment
TechWell
 
Gaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platformGaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platformSimba Events
 
Demo of NABH Documentation Kit for Pre Accreditation
Demo of NABH Documentation Kit for Pre AccreditationDemo of NABH Documentation Kit for Pre Accreditation
Demo of NABH Documentation Kit for Pre Accreditation
Global Manager Group
 
Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...
Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...
Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...dclsocialmedia
 
Maintaining A Materials Declaration System
Maintaining A Materials Declaration SystemMaintaining A Materials Declaration System
Maintaining A Materials Declaration System
raj takhar
 
handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...
handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...
handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...
HERNANALBERTOTELLEZV
 
Generis Company Presentation for RIM
Generis Company Presentation for RIMGeneris Company Presentation for RIM
Generis Company Presentation for RIM
Generis
 
Adalimumab- comprehensive patent search
Adalimumab- comprehensive patent searchAdalimumab- comprehensive patent search
Adalimumab- comprehensive patent search
Kate Cleverley
 
Aagami Inc. Research Services Presentation
Aagami Inc. Research Services PresentationAagami Inc. Research Services Presentation
Aagami Inc. Research Services PresentationGodwyn Francis
 
Pharma Regulatory & licensing Service
Pharma Regulatory & licensing ServicePharma Regulatory & licensing Service
Pharma Regulatory & licensing Service
Vikram sathish Asokan
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
KusumaLathaBeera1
 
Maetrics: The ROI of Good Quality & Compliance
Maetrics: The ROI of Good Quality & ComplianceMaetrics: The ROI of Good Quality & Compliance
Maetrics: The ROI of Good Quality & Compliance
Generis
 
Regulatory affairs by sachin gundecha
Regulatory affairs by sachin gundechaRegulatory affairs by sachin gundecha
Regulatory affairs by sachin gundecha
Sachin Gundecha
 
Corneal Graft Rejection - Pipeline Insight, 2018
Corneal Graft Rejection - Pipeline Insight, 2018Corneal Graft Rejection - Pipeline Insight, 2018
Corneal Graft Rejection - Pipeline Insight, 2018
Market Research Reports, Inc.
 
Acute Lung Injury - Pipeline Insight, 2018
Acute Lung Injury - Pipeline Insight, 2018Acute Lung Injury - Pipeline Insight, 2018
Acute Lung Injury - Pipeline Insight, 2018
Market Research Reports, Inc.
 
Pharmaceutical Technology Transfer Best Practices
Pharmaceutical Technology Transfer Best PracticesPharmaceutical Technology Transfer Best Practices
Pharmaceutical Technology Transfer Best Practices
Anthony Grenier
 
Big Data Analysis for Standard Essential Patents
Big Data Analysis for Standard Essential PatentsBig Data Analysis for Standard Essential Patents
Big Data Analysis for Standard Essential Patents
Alex G. Lee, Ph.D. Esq. CLP
 
HMIRA Trade Secret Registrations in Canada
HMIRA Trade Secret Registrations in CanadaHMIRA Trade Secret Registrations in Canada
HMIRA Trade Secret Registrations in Canada
Dell Tech
 

Similar to Liraglutide - Comprehensive patent search (20)

US FDA Quality Metrics Technical Conformance Guide
US FDA  Quality Metrics Technical  Conformance GuideUS FDA  Quality Metrics Technical  Conformance Guide
US FDA Quality Metrics Technical Conformance Guide
 
Implementing Agile in an FDA Regulated Environment
Implementing Agile in an FDA Regulated EnvironmentImplementing Agile in an FDA Regulated Environment
Implementing Agile in an FDA Regulated Environment
 
Gaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platformGaining business excellence by leveraging plm platform
Gaining business excellence by leveraging plm platform
 
Demo of NABH Documentation Kit for Pre Accreditation
Demo of NABH Documentation Kit for Pre AccreditationDemo of NABH Documentation Kit for Pre Accreditation
Demo of NABH Documentation Kit for Pre Accreditation
 
Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...
Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...
Best Practices: Cutting Through the Confusion & Avoiding the Pitfalls of Crea...
 
Maintaining A Materials Declaration System
Maintaining A Materials Declaration SystemMaintaining A Materials Declaration System
Maintaining A Materials Declaration System
 
handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...
handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...
handbook_of_pharmaceutical_manufacturing_formulations__second_edition__volume...
 
Generis Company Presentation for RIM
Generis Company Presentation for RIMGeneris Company Presentation for RIM
Generis Company Presentation for RIM
 
Adalimumab- comprehensive patent search
Adalimumab- comprehensive patent searchAdalimumab- comprehensive patent search
Adalimumab- comprehensive patent search
 
Aagami Inc. Research Services Presentation
Aagami Inc. Research Services PresentationAagami Inc. Research Services Presentation
Aagami Inc. Research Services Presentation
 
Docmentation complete
Docmentation completeDocmentation complete
Docmentation complete
 
Pharma Regulatory & licensing Service
Pharma Regulatory & licensing ServicePharma Regulatory & licensing Service
Pharma Regulatory & licensing Service
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
 
Maetrics: The ROI of Good Quality & Compliance
Maetrics: The ROI of Good Quality & ComplianceMaetrics: The ROI of Good Quality & Compliance
Maetrics: The ROI of Good Quality & Compliance
 
Regulatory affairs by sachin gundecha
Regulatory affairs by sachin gundechaRegulatory affairs by sachin gundecha
Regulatory affairs by sachin gundecha
 
Corneal Graft Rejection - Pipeline Insight, 2018
Corneal Graft Rejection - Pipeline Insight, 2018Corneal Graft Rejection - Pipeline Insight, 2018
Corneal Graft Rejection - Pipeline Insight, 2018
 
Acute Lung Injury - Pipeline Insight, 2018
Acute Lung Injury - Pipeline Insight, 2018Acute Lung Injury - Pipeline Insight, 2018
Acute Lung Injury - Pipeline Insight, 2018
 
Pharmaceutical Technology Transfer Best Practices
Pharmaceutical Technology Transfer Best PracticesPharmaceutical Technology Transfer Best Practices
Pharmaceutical Technology Transfer Best Practices
 
Big Data Analysis for Standard Essential Patents
Big Data Analysis for Standard Essential PatentsBig Data Analysis for Standard Essential Patents
Big Data Analysis for Standard Essential Patents
 
HMIRA Trade Secret Registrations in Canada
HMIRA Trade Secret Registrations in CanadaHMIRA Trade Secret Registrations in Canada
HMIRA Trade Secret Registrations in Canada
 

Liraglutide - Comprehensive patent search

  • 1. Liraglutide - Comprehensive patent search Report Details: Published:November 2012 No. of Pages: Price: Single User License – US$7200 Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait. Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information. Pipeline Developer features: •Comprehensive patent searching, covering the world's key territories (see 'search coverage' below) •Identifies patents covering molecule, formulation, process, use, combination and assay techniques (see 'Patent Categories Identified'below) •Patent identification, categorisation and interpretation •Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims •Manual filtration of patents not relevant to generic development •Updated on a monthly basis, including changes to patent families, statuses, and litigation •Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers Patent Categories Identified: 1. Molecular Form a) Molecule Patents b) Salts, Hydrates & Solvates c) Polymorphic Forms d) Other Molecular Forms 2. Active Ingredient Preparation a) Intermediates & Preparation Thereof b) Final Synthetic Stages c) Complete Synthesis d) Purification Methods
  • 2. e) Fermentation Methods f) Biotechnology 3. Formulations & Methods Thereof a) General Formulations & Methods b) Injectable Formulations c) Oral Formulations d) Other Administration-Specific Formulations e) Excipients, Kits & Packaging 4. Related Medical Use & Administration a) New Use Related to Main Indication b) Dosing Regimen/Administration Conditions 5. Active Ingredient Combinations a) Novel Combinations b) Use of Combinations c) Dosing Regimen & Administration Conditions for Combinations 6. Analytical Methods a) Assaying Methods b) Methods of Determining Patient Suitability Search coverage: Clicking on a patent family displays detailed information on the 'Core' and 'Non-Core' 'Patent Family Equivalents'. 'Core Patent Family Equivalents' are equivalent patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. Statuses are also monitored and updated. 'Extended Patent Family Equivalents' are equivalent patents found through the INPADOC database, increasing the search coverage to 70 countries. Patent and national register access: Clicking on a listed patent/application number or text or image link will launch a pop-up window containing an image of the patent, enabling easy analysis of the patent documents. Clicking on a register link launches a pop-up window with the patent office register extract for that patent. This allows investigation into the examination status of a pending patent, opposition of a granted patent and/or payment of maintenance fees. Please note that no extra charges apply to accessing or downloading documents of any kind. Litigation alerts: Informing you of developments in court, litigation alerts can also be accessed by clicking on the litigation symbol next to the status, with links to judgements where available. Updating: To take the time and hassle out of monitoring and updating a large number of patents, all Pipeline Developer reporting is updated on a monthly basis. Convenient change flags identify new patent families, new patent family members, changes in statuses and litigation alerts. Legal status and transaction history: You can also find legal status and transaction history for 'Extended Patent Family Equivalents' by clicking on the INPADOC Family/Legal Status button for 65 additional territories.
  • 3. Reporting and access: All data can be exported into Microsoft Excel and print friendly versions for ease of data manipulation and reporting. Company details are confidential and all data is SSL secure. Five users per company are permitted and access levels are controlled by a nominated 'company administrator'. Pipeline Developer is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite. Get your copy of this report @ http://www.reportsnreports.com/reports/206873-liraglutide-comprehensive-patent-search.html Major points covered in Table of Contents of this report include N/A Contact: sales@reportsandreports.com for more information.